Early Access
A long time ago, I saw a pharmaceutical product get delayed for two years. After clinical trials, the team couldn't understand why there was no difference between the negative control and the drug. The team spent several months looking at data.
After a lot of investigations, the Research and Development group realized that the protein was the wrong protein. So, back to square one they went. The research team recloned the molecule from scratch. After half a year, the clinical trials could resume.
Continue reading on LinkedIn pulse: How much is two years worth?